START在 Moderna的 mRNA-4106（一种泛肿瘤抗原疗法候选药物）针对实体瘤的 1期临床试验中，对美国首位患者进行了给药-动脉网

START Doses First U.S. Patient in Moderna's Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor Antigen Therapy Candidate, in Solid Tumors

CISION 等信源发布 2025-05-15 20:01



可切换为仅中文







Major study milestone highlights START's commitment to bringing novel cancer therapies to patients through community-based early-phase clinical trials

重大研究里程碑凸显了START通过基于社区的早期临床试验为患者带来新型癌症疗法的承诺。

SAN ANTONIO

圣安东尼奥

，

May 15, 2025

2025年5月15日

/PRNewswire/ -- The START Center for Cancer Research ('START'), the world's largest early-phase community-based oncology site network, today announced the dosing of the first U.S. participant in Moderna's Phase 1 study evaluating mRNA-4106, a novel Pan-Tumor Antigen Therapy candidate, in patients with advanced or metastatic solid tumors..

/PRNewswire/ -- 全球最大的早期阶段社区肿瘤学研究网络START癌症研究中心（START）今日宣布，首位美国参与者已在Moderna的1期研究中接受给药，该研究评估了新型泛肿瘤抗原疗法候选药物mRNA-4106在晚期或转移性实体瘤患者中的效果。

The first dose was administered at START

第一剂于开始时接种

San Antonio

圣安东尼奥

by Dr.

由博士。

Amita Patnaik

阿米塔·帕特奈克

who shared, 'mRNA represents a bold new frontier in cancer immunotherapy, and we're proud to provide our patients access to this innovative treatment as part of a first-in-human trial. At START, our mission is to ensure that scientific breakthroughs translate into real-world options for patients—this study is a powerful example of that commitment.'.

“mRNA 代表了癌症免疫治疗的一个大胆的新领域，我们很自豪能为患者提供这种创新疗法，作为首次人体试验的一部分。在 START，我们的使命是确保科学突破转化为患者的现实选择——这项研究正是这一承诺的有力例证。”

The Phase 1 trial (ClinicalTrials.gov identifier:

一期试验（ClinicalTrials.gov 标识符：

NCT06880549

) will evaluate the safety, pharmacodynamics, immunogenicity and preliminary efficacy of mRNA-4106 administered alone and in combination with checkpoint inhibitor therapy. mRNA-4106's multivalent approach aims to broaden treatment options for patients with cancer, advancing the field beyond single-targeted immunotherapies..

）将评估单独使用和与检查点抑制剂疗法联合使用时，mRNA-4106的安全性、药效学、免疫原性和初步疗效。mRNA-4106的多价方法旨在拓宽癌症患者的治疗选择，推动该领域超越单一靶向免疫疗法。

'This milestone reflects the core of who we are at START - accelerating the next generation of cancer therapies by bringing them directly to patients in the communities where they live,' said

“这一里程碑反映了我们在START的核心使命——通过将下一代癌症疗法直接带给患者，加速其发展，让患者在自己生活的社区中就能获得治疗，”

Nick Slack

尼克·斯莱克

, MBE, Chairman and CEO of START. 'We're proud to support Moderna in advancing this innovation into the clinic, reinforcing our commitment to faster, more accessible early phase trials that expand opportunity and impact for patients and sponsors alike.'

，START董事长兼首席执行官MBE表示：“我们很自豪能够支持Moderna将这一创新推进到临床，这再次证明了我们致力于更快、更易获取的早期试验，为患者和赞助方创造更多机会与影响。”

'With mRNA-4106, we sought to design an inclusive therapy that encodes for antigens commonly shared across patients and tumor types. We are thrilled to be able to bring this medicine to trial participants, and in partnership with forward-thinking site networks like START, further showcase the promise of mRNA to transform cancer care,' said Dr.

“通过mRNA-4106，我们旨在设计一种包容性疗法，编码跨患者和肿瘤类型常见的抗原。我们非常高兴能够将这种药物带给试验参与者，并与像START这样具有前瞻思维的机构网络合作，进一步展示mRNA在改变癌症治疗方面的潜力，”博士表示。

。

Rose Loughlin

罗斯·洛林

, Executive Vice President of Research at Moderna.

现代研究公司的执行副总裁。

START's participation in this trial reinforces its leadership in accelerating access in transformative therapies, delivering on its mission of 'Hope Through Access' for patients worldwide.

START参与此次试验进一步巩固了其在加速获取变革性疗法方面的领导地位，实现了其“通过获取带来希望”的使命，为全球患者服务。

About The START Center for Cancer Research

关于START癌症研究中心

Deeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START clinical trial sites have conducted more than a thousand early-phase clinical trials, including for 45 therapies that were approved by the FDA or EMA.

全球社区肿瘤中心的深厚根基使START癌症研究中心能够为新型抗癌药物提供专业的临床前和早期临床试验。START临床试验站点已经开展了上千项早期临床试验，其中包括45种获得FDA或EMA批准的疗法。

START represents the world's largest roster of early-phase Principal Investigators (PIs) across its ten clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world. Learn more at .

START 汇集了其十个临床试验基地中全球规模最大的早期阶段主要研究者（PI）团队。致力于加速从试验到治疗的进程，START 为全球患者、家属和医生带来希望。欲了解更多信息，请访问。

STARTresearch.com

起点研究.com

。

START Contacts

开始联系人

Lauren Panco

劳伦·潘科

VP, Marketing

副总裁，营销部

609-216-4920

Lauren.panco@startresearch.com